The factors in favour of a rise in the Genfit share price:
First of all, Genfit's first asset, and undoubtedly the point that has enabled it to achieve its current position and reputation, is of course its specialization in certain advanced treatments and patents. Indeed, this biopharmaceutical company develops solutions for the early diagnosis, prevention and treatment of cardiometabolic diseases such as diabetes or dyslipidemia, which are increasingly common in the world population. More recently, Genfit has also made real progress in the search for treatments for NASH, a non-alcoholic steatotic liver disorder, and for other types of diseases affecting the liver or intestines. These specialties allow the company to sell its products very easily on a booming market.
Genfit's strategy of effectively compartmentalizing its portfolio into five major programs is another advantage for the company, as it does not put all its eggs in one basket and avoids the risks associated with a single research area. For example, Genfit has one program dedicated to Elafibranor or GFT505, a treatment currently in clinical trials for NASH. Two programs are also underway in biomarkers for type 2 diabetes. Another program is focused on circadian rhythm disturbances associated with type 2 diabetes. Another program is focused on immune system dysregulation targeting the liver or intestines and a final program is focused on liver or intestinal fibrosis mechanisms with pharmacological validation underway.
The fact that type 2 diabetes-related diseases are currently increasing in number and prevalence is also a strong point for Genfit, which can benefit from the growing market for these diseases due to obesity, as well as NASH diseases, which currently affect between 12 and 17% of Americans.
Genfit can also count on its strong investment in research and development and on the partnerships it regularly sets up, as was the case with Sanofi, which enable it to obtain excellent results and truly innovative solutions.
Finally, Genfit's last advantage concerns the NASH diseases we mentioned above, which are really expanding. Indeed, Genfit has already filed a patent for GFT505 for the European and US market in 2014. This treatment will thus be protected by this patent until 2035. In addition, this treatment has exceptionally received accelerated review status from the FDA in the United States due to the increasing proportion of the population suffering from these NASH disorders and the urgent need to find an effective solution to this health problem.